Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

27 April 2022

FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST

29 March 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

28 March 2022

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

4 March 2022

Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico

18 February 2022

HAS launches as an independent business

14 January 2022

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes

14 January 2022

Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements

21 December 2021

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQTM (infigratinib) in Canada

21 December 2021

The 3rd Sustainability Report confirms IBSA’s commitment to the well-being of the Person

20 December 2021